Press Releases

Washington, DC – USAgainstAlzheimer’s, the national movement committed to finding a cure for Alzheimer’s by 2020, today officially launched ClergyAgainstAlzheimer’s, a diverse, multifaith network of clergy working to focus our nation’s attention on the impact of Alzheimer’s disease on American families.

Two announcements made at the Alzheimer’s Association International Conference (AAIC) in Copenhagen show encouraging progress in the fight to find a cure for Alzheimer’s by 2020, according to George Vradenburg, who participated in the conference as Convener of the Global CEO Initiative on Alzheimer’s and who also is Founder of USAgainstAlzheimer’s.

“We now have encouraging progress on two fronts for drug developments, for diagnosis and even for curing some forms of this terrible disease,” Vradenburg said.

Washington, DC – The Global CEO Initiative on Alzheimer’s Disease (CEOi) today announced that the Roche Group, a leading global healthcare company, will join the CEOi as part of its ongoing effort to advance innovations in research and drug development to stop Alzheimer’s by 2025.  Roche is at the forefront of Alzheimer’s research and drug development, and is a recognized leader in innovation and developing differentiated medicines.

Washington, DC – African Americans are two to three times more likely to develop Alzheimer’s disease than white Americans, yet they are less likely to be diagnosed.  While Alzheimer’s is the sixth leading cause of death in the United States, it is the fourth leading cause of death for older African Americans. 

Alzheimer’s is the only disease in the top ten that currently has no cure, treatment, or prevention.

Washington, DC – A key Senate committee included $100 million in additional funding for Alzheimer’s research at the National Institutes of Health (NIH), acting just days before today’s briefing on new mortality data that suggests more than a half-million U.S. deaths every year are attributable to Alzheimer’s disease, making it the third leading cause of death.


^ Back to Top